Moody Aldrich Partners LLC increased its stake in shares of Albany Molecular Research Inc. (NASDAQ:AMRI) by 169.3% during the second quarter, Holdings Channel reports. The firm owned 125,257 shares of the company’s stock after buying an additional 78,752 shares during the period. Albany Molecular Research makes up 1.4% of Moody Aldrich Partners LLC’s investment portfolio, making the stock its 22nd largest position. Moody Aldrich Partners LLC’s holdings in Albany Molecular Research were worth $1,683,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors also recently added to or reduced their stakes in the stock. BNP Paribas Arbitrage SA raised its position in Albany Molecular Research by 116.1% in the second quarter. BNP Paribas Arbitrage SA now owns 8,329 shares of the company’s stock valued at $112,000 after buying an additional 4,475 shares during the period. Louisiana State Employees Retirement System raised its position in Albany Molecular Research by 0.8% in the second quarter. Louisiana State Employees Retirement System now owns 12,000 shares of the company’s stock valued at $161,000 after buying an additional 100 shares during the period. Pacad Investment Ltd. bought a new position in Albany Molecular Research during the first quarter valued at approximately $197,000. Arizona State Retirement System raised its position in Albany Molecular Research by 3.0% in the first quarter. Arizona State Retirement System now owns 13,786 shares of the company’s stock valued at $211,000 after buying an additional 400 shares during the period. Finally, Capstone Asset Management Co. raised its position in Albany Molecular Research by 18.2% in the second quarter. Capstone Asset Management Co. now owns 16,950 shares of the company’s stock valued at $228,000 after buying an additional 2,610 shares during the period. 71.39% of the stock is currently owned by institutional investors.

Shares of Albany Molecular Research Inc. (NASDAQ:AMRI) traded up 1.83% during mid-day trading on Thursday, hitting $16.17. The stock had a trading volume of 246,657 shares. The stock has a 50-day moving average price of $14.94 and a 200 day moving average price of $14.61. Albany Molecular Research Inc. has a 52 week low of $12.45 and a 52 week high of $20.65. The stock’s market cap is $558.33 million.

Albany Molecular Research (NASDAQ:AMRI) last posted its quarterly earnings data on Thursday, August 4th. The company reported $0.36 earnings per share for the quarter, topping the consensus estimate of $0.32 by $0.04. Albany Molecular Research had a negative net margin of 7.37% and a positive return on equity of 3.17%. The firm had revenue of $116.50 million for the quarter, compared to analysts’ expectations of $123.10 million. On average, equities analysts forecast that Albany Molecular Research Inc. will post $1.07 EPS for the current fiscal year.

Separately, Morgan Stanley reissued a “buy” rating and issued a $17.00 price objective on shares of Albany Molecular Research in a research report on Friday, August 5th.

About Albany Molecular Research

Albany Molecular Research, Inc is a global contract research and manufacturing company. The Company provides drug discovery, development, and manufacturing services. The Company operates through three segments: Discovery and Development Services (DDS), Active Pharmaceutical Ingredients (API) and Drug Product Manufacturing (DPM).

5 Day Chart for NASDAQ:AMRI

Want to see what other hedge funds are holding AMRI? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Albany Molecular Research Inc. (NASDAQ:AMRI).

Receive News & Ratings for Albany Molecular Research Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Albany Molecular Research Inc. and related companies with MarketBeat.com's FREE daily email newsletter.